DARZALEX® Dosing in the DVMP Regimen



DARZALEX® + Velcade® (bortezomib) + melphalan + prednisone

DARZALEX® dosing frequency decreases over time1

In newly diagnosed multiple myeloma (NDMM) transplant-ineligible patients

  • DARZALEX® is given as an intravenous (IV) infusion after dilution at 16 mg/kg of actual body weight
  • Bortezomib 1.3 mg/m2 is administered by subcutaneous injection twice weekly at Weeks 1, 2, 4, and 5 (Cycle 1) followed by once weekly at Weeks 1, 2, 4, and 5 (Cycles 2 to 9)
    • Melphalan and prednisone are orally administered on Days 1 through 4 for each of the first 9 cycles
    • VMP administration should be stopped after 9 cycles
  • On DARZALEX® infusion days, 20 mg of dexamethasone was given orally or IV as a pre-infusion medication and was continued as a pre-medication after VMP discontinuation
    • Additional background regimen-specific corticosteroids (eg, prednisone) should not be taken on DARZALEX® infusion days
Continue DARZALEX® until disease progression or unacceptable toxicity1

*Until disease progression or unacceptable toxicity.

To facilitate administration, the first prescribed 16 mg/kg dose at Week 1 may be split over 2 consecutive days. (Please see full Prescribing Information to learn more about split first dose.)

Velcade® is a registered trademark of Millenium Pharmaceuticals, Inc.

Starting at Cycle 10 (Week 55+), administration frequency for DARZALEX® is once every 4 weeks and requires a median duration of 3.4 hours1

Median duration of 16 mg/kg infusion decreased after the first infusion1

Week 1 infusions of DARZALEX® can be administered as a split dose on 2 consecutive days. Median duration of infusion decreases to 3 hours after Week 2.

Median infusion length for subsequent infusions (Week 2+ in aggregate). Administer the Week 2 (16 mg/kg) infusion according to the infusion rates outlined in Table 4 of the DARZALEX® Prescribing Information.1

Want a PDF of the DARZALEX® + VMP dosing schedule?

Looking for a comprehensive guide to DARZALEX® dosing & administration?

  • DARZALEX® should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur1
  • If a planned dose of DARZALEX® is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval1

Interference with serological testing1

  • Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test)
  • Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion
  • Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type is not impacted
  • Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX®
  • Type and screen patients prior to starting DARZALEX®

Find out more about interference with serological testing for patients being treated with DARZALEX®

Provide this document to patients to let healthcare professionals know that the patient is being treated with DARZALEX®


DARZALEX® + VMP Interactive Calendar


DARZALEX<sup>®</sup> + VMP Interactive Calendar

Select the date on which you plan to initiate your patient’s first DARZALEX® infusion. Once a date is selected, recommended subsequent infusion dates will automatically populate within the calendar.§

Select a date to begin

Select the date on which you plan to initiate your patient’s first DARZALEX® infusion. Once a date is selected, recommended subsequent infusion dates will automatically populate within the calendar.§

Select a date to begin

Infusion Dates
Weeks 1-8
Weekly Infusions
Weeks 1-8 (weekly infusions)
Weeks 9-24
Infusions Every 2 Weeks
Weeks 9-24 (infusions every 2 weeks)
Weeks 25+
Infusions Every 4 Weeks
Weeks 25+ (infusions every 4 weeks)

§Please note that dates provided are recommendations for infusion visits only. These dates do not account for additional follow-up/care visits. Infusion dates may change depending on patient and office availability.

Infusion centers may not offer weekend and/or holiday appointments.

Please contact the center to confirm hours of operation.

You have chosen a new start date.

Would you like to clear your old dosing schedule and create a new one?

Please select the date you plan to give the patient as first DARZALEX® dose.
Please choose a dosing regimen.
DARZALEX® + bortezomib + melphalan + prednisone
Choose PDF type

Please select the view mode for your dosing calendar.

Looking to give this dosing schedule to your patient?